Cutaneous metastases of breast cancer during adjuvant chemotherapy correlates with increasing CD44⁺/CD24⁻ and ALDH-1 expression: a case report and literature review

Jung Sun Lee¹, Woo Gyeong Kim²

¹Department of Surgery, ²Department of Pathology, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea

Correspondence to: Jung Sun Lee, MD, PhD. Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan 48108, Korea. Email: gsjslee@gmail.com.

Abstract: Cancer stem cells (CSCs) within a tumor are scarce and self-sustaining and they have the abilities for self-renewal and the potential of giving rise to diverse types of cells that compose the tumor. These cells are suggested to be associated with therapeutic failure, and therefore they remain as an important issue in this regard. We report the cases of two breast cancer patients diagnosed with rapid cutaneous metastases during adjuvant cytotoxic chemotherapy after curative mastectomy. For elucidating a relationship between CSCs and resistance to chemotherapy, we evaluated primary tumor and metastatic cutaneous lesions by CSC markers in immunohistochemical stains (CD44⁺/CD24⁻ and ALDH-1). Either CD44⁺/CD24⁻ or ALDH-1 expression increased compared to primary breast cancer during chemotherapy. This case report shows that CD44⁺/CD24⁻ or ALDH-1 expression in primary or cutaneous metastatic breast cancer may be associated with rapid onset chemoresistance.

Keywords: Breast neoplasm; cancer stem cell (CSC); cutaneous; metastasis

Received: 12 January 2018; Accepted: 28 February 2018; Published: 27 March 2018.

doi: 10.21037/sci.2018.03.04

View this article at: <http://dx.doi.org/10.21037/sci.2018.03.04>

Introduction

Cutaneous metastasis from a solid tumor indicates the spread of cancer to the body surface. It accounts for 2% of all skin tumors, but the rate of cutaneous metastasis in patients with breast cancer is as high as 23.9% (1-3). To avoid this frustrating and burdensome situation, the clinical impact of cutaneous metastases is crucial, not only from an academic point of view, but also in improving patient management. The expressions of CD44⁺/CD24⁻ and ALDH-1 on cell surfaces have been suggested to have tumor-initiating properties with stem cell-like and invasive features (4-6). Several experimental and preclinical studies have pointed out that cancer stem cells (CSCs) may be one of major key players to create genomic instabilities and are difficult to eradicate with anti-neoplastic agents (7-12). In our institute, a few breast cancer patients with cutaneous metastases during postoperative chemotherapy treatment were encountered. However, there are rare reports of

cutaneous metastasis during chemotherapy after curative surgery. We hypothesize that these tumors are derived from residual CSCs with chemoresistant properties. In this study, we reported trends of expression of CSCs in primary and metastatic lesions which occurred during chemotherapy.

Case presentation

Case 1

A 37-year-old woman was diagnosed with locally advanced cancer of the left breast in February 2011. She underwent a total mastectomy with axillary lymph node dissection due to multi-focal breast cancer (pT1N2). The pathology report showed that lymphovascular invasions (LVI) were present without dermal lymphatic involvement. The immunohistochemical analysis revealed *HER2* immunophenotype and with positive expressions of the CSC markers, CD44⁺/CD24⁻ and ALDH-1 (>90% and

Figure 1 Double immunohistochemical analyses of CD44 (red)/CD24 (brown), and single IHC stain of ALDH-1 in breast cancers of case 1 (magnification $\times 200$, scale bar 100 μm). Expressions of CD44/CD24 (A) and ALDH-1 (B) in primary breast cancer. Expressions of CD44/CD24 (C) and ALDH-1 (D) in cutaneous metastatic ductal carcinoma. Expressions of CD44/CD24 (E) and ALDH-1 (F) in brain metastasis.

$<10\%$, respectively) (Figure 1A and 1B, respectively). Adjuvant chemotherapy treatment with four cycles of anthracycline (AC) followed by four cycles of docetaxel (T) and 18 cycles of trastuzumab (H) were planned. However, after one cycle of T, multiple firm erythematous papules and nodules on the left previous skin incision site were noted which was subsequently confirmed as a metastatic ductal carcinoma in a punch biopsy. The expressions of CD44⁺/CD24⁻ and ALDH-1 in metastatic cutaneous lesions after surgery were also positive ($>90\%$ and 20–30%, respectively) (Figure 1C and 1D, respectively). A

few more cytotoxic chemotherapy sessions were applied, but eventually the disease metastasized to the brain and it was surgically removed. Expressions of CD44⁺/CD24⁻ and ALDH-1 in the brain metastatic lesions were also positive with a slight increase in ALDH-1 ($>90\%$ and 30%, respectively) (Figure 1E and 1F, respectively).

Case 2

A 51-year-old woman diagnosed with invasive breast cancer had undergone a skin-sparing mastectomy with implant

Figure 2 Double immunohistochemical analyses of CD44 (red)/CD24 (brown), and single IHC stain of ALDH-1 in breast cancers of case 2 (magnification $\times 200$, scale bar 100 μm). Expressions of CD44/CD24 (A) and ALDH-1 (B) in primary breast cancer. Expressions of CD44/CD24 (C) and ALDH-1 (D) in cutaneous metastatic ductal carcinoma.

reconstruction in June 2016 (pT3N3). The intrinsic subtype of her breast cancer was triple negative but *HER-2* showed strong membranous expression in the ductal carcinoma *in situ* component around invasive ductal carcinoma. Microscopic findings also revealed multiple LVIs. The expressions of CD44⁺/CD24⁺ and ALDH-1 were positive (50% and 50%, respectively) (Figure 2A and 2B, respectively). She subsequently started adjuvant chemotherapy with four cycles of AC and followed by four cycles of T. After one cycle of T, diffuse erythematous patches were found with tenderness on the entire skin of the left breast. A punch biopsy of the lesion confirmed metastatic ductal carcinoma. The expressions of CD44⁺/CD24⁺ and ALDH-1 in the metastatic cutaneous lesion after surgery increased to 60% and 60%, respectively (Figure 2C and 2D, respectively). Subsequently, she underwent several sessions of cytotoxic chemotherapy, but after two months, skin metastasis also occurred on the contralateral left chest wall.

Discussion

Several studies (13-17) have reported a relationship between

CSCs and chemoresistance in human breast cancer tissues. Lee *et al.* (13) suggested the chemoresistant property of putative CD44⁺/CD24⁺ and ALDH-1 to the conventional AC-based chemotherapy by demonstrating an increase in the proportion of CSCs after preoperative systemic therapy, and also significantly shorter disease-free survival (DFS) rate was observed compared to no change or decrease in the putative CSC population. Even though the survival rate was analyzed only in the non-pCR group, increased CD44⁺/CD24⁺ and ALDH-1(+) population resulted with a worse survival rate. Seo *et al.* (14) analyzed the expressions of the breast CSC markers, CD44⁺/CD24⁺ and ALDH-1(+), and clinical outcomes in *HER-2* positive breast cancers which had been treated with surgery and additional adjuvant chemotherapy and trastuzumab. The study showed that CD44⁺/CD24⁺ but not ALDH-1(+), was an independent prognostic factor for poor DFS and overall survival (OS) when adjuvant trastuzumab was applied. This could also imply that resistance to trastuzumab may be derived from CD44⁺/CD24⁺ CSC cells. Other previous comparative studies (15-19) using paired human breast cancer tissues obtained pre- and post-chemotherapy, showed that

CD44⁺/CD24⁻ (17) or ALDH-1(+) (16) tumor cells increased significantly after chemotherapy. However, other literature detected no significant enrichment of ALDH-1(+) tumor cells (18) or even a reduction in CD44⁺/CD24⁻ cells (19) after chemotherapy. However, the latter study (19) also reported that patients with tumors containing high numbers of CD44⁺/CD24⁻ cells more frequently developed bone metastases in the course of the disease.

The molecular mechanisms underlying the roles of breast CSCs in chemoresistance have been reported in several studies (20,21) and proposed clinical implication for breast cancer therapeutics (22-25). The occurrence of a fraction of breast CSCs with increased multidrug resistance (MDR) affinity clinically may be an additional mechanism for the positive selection of breast CSCs during chemotherapy (20). Koshkin *et al.* (21) showed that in a certain range of concentrations of chemotherapeutic agents, MDR transports in breast CSC with improved affinity will be better saturated with substrate than those in bulk cells. Even without expression effects, MDR transport and chemoresistance in breast CSCs will exceed those in bulk cells. This difference provided an additional mechanism for the increase in breast CSC content in tumors subjected to chemotherapy. Van Phuc *et al.* (22) showed that down regulation of CD44 with siRNAs reduced doxorubicin resistance of CD44⁺/CD24⁻ breast cancer cell and suppression of human breast tumors in NOD/SCIA mice by CD44 shRNA gene therapy combined with doxorubicin treatment (23). Bontempo *et al.* (24) suggested that molecular iodine was able to reduce the drug resistance and invasive capacity of mammary cancer cells exposed to doxorubicin and could be used as an anti-chemoresistant agent with clinical potential. Saha *et al.* (25) demonstrated that disruptions to the NFκB-IL6 feedback loop prevented CSC induction and sensitized preexisting CSCs to chemotherapy, so that combining aspirin and conventional chemotherapy might offer a new treatment strategy to improve recurrence-free survival of breast cancer patients.

Most translation studies regarding CSC expression were evaluated and compared in preoperative needle biopsies prior to chemotherapy and in post-neoadjuvant surgical specimens. However, due to the heterogeneity of breast cancers and the small population of CSCs, undetected CSCs can exist, especially in small samples such as needle biopsies. Also, in the setting of neoadjuvant chemotherapy, residual damaged cancer cells, not CSC, could be changed to CSC through reprogramming mechanisms (26-28), and increased CSCs after chemotherapy may be caused not only

by proliferation of previous CSCs but also reprogrammed new CSCs.

In the two cases, although mastectomy was performed to completely remove both residual tumors and surrounding breast tissue, rapid cutaneous metastases occurred during chemotherapy. The primary breast tumors of the two cases showed LVI and relatively high expressions of CD44⁺/CD24⁻ and ALDH-1(+). Expressions of CSCs had increased in metastatic cutaneous lesions during chemotherapy. We hypothesized that in operation fields normal cutaneous stem cells could acquire more aggressive proliferative properties with cancer stemness in spite of chemotherapy, or dysregulated cells with self-renewal could undergo cutaneous metastasis. Although we cannot rule out the fact that the dramatic deterioration reflects the natural course of an extremely unfavorable breast cancer variant, the temporal coincidence is highly indicative of the causative role of CSCs. This underlines that more clinical data are needed to assess whether cancer stemness can be carried out in the chemotherapy resistance.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Informed Consent: Written informed consent was obtained from the patients for publication of this Case Report and any accompanying images.

References

1. Hu SC, Chen GS, Wu CS, et al. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. *J Am Acad Dermatol* 2009;60:379-87.
2. Kong JH, Park YH, Kim JA, et al. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations. *Oncology* 2011;81:55-62.
3. Krathen RA, Orenge IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. *South Med J* 2003;96:164-7.
4. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary

- stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 2007;1:555-67.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003;100:3983-8.
 6. Li W, Ma H, Zhang J, et al. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. *Sci Rep* 2017;7:13856.
 7. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. *J Clin Oncol* 2008;26:2813-20.
 8. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? *Nat Rev Drug Discov* 2014;13:497-512.
 9. Guo W. Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. *Stem Cells Transl Med* 2014;3:942-8.
 10. Cojoc M, Mabert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. *Semin Cancer Biol* 2015;31:16-27.
 11. Colak S, Medema JP. Cancer stem cells--important players in tumor therapy resistance. *FEBS J* 2014;281:4779-91.
 12. Gong W, Sun B, Sun H, et al. Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells. *Am J Cancer Res* 2017;7:503-17.
 13. Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. *Br J Cancer* 2011;104:1730-8.
 14. Seo AN, Lee HJ, Kim EJ, et al. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. *Br J Cancer* 2016;114:1109-16.
 15. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. *Breast Cancer Res* 2008;10:R25.
 16. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. *Clin Cancer Res* 2009;15:4234-41.
 17. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. *J Natl Cancer Inst* 2008;100:672-9.
 18. Resetskova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. *Breast Cancer Res Treat* 2010;123:97-108.
 19. Aulmann S, Waldburger N, Penzel R, et al. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. *Hum Pathol* 2010;41:574-81.
 20. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. *Drug Resist Updat* 2010;13:99-108.
 21. Koshkin V, Yang BB, Krylov SN. Kinetics of MDR transport in tumor-initiating cells. *PLoS One* 2013;8:e79222.
 22. Van Phuc P, Nhan PL, Nhung TH, et al. Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. *Onco Targets Ther* 2011;4:71-8.
 23. Van Pham P, Vu NB, Duong TT, et al. Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. *Onco Targets Ther* 2012;5:77-84.
 24. Bontempo A, Ugalde-Villanueva B, Delgado-Gonzalez E, et al. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin. *Oncol Rep* 2017;38:2867-76.
 25. Saha S, Mukherjee S, Khan P, et al. Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFkappaB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. *Cancer Res* 2016;76:2000-12.
 26. Yates LR, Gerstung M, Knappskog S, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. *Nat Med* 2015;21:751-9.
 27. Balko JM, Giltane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. *Cancer Discov* 2014;4:232-45.
 28. Desmedt C, Yates L, Kulka J. Catalog of genetic progression of human cancers: breast cancer. *Cancer Metastasis Rev* 2016;35:49-62.

doi: 10.21037/sci.2018.03.04

Cite this article as: Lee JS, Kim WG. Cutaneous metastases of breast cancer during adjuvant chemotherapy correlates with increasing CD44+/CD24- and ALDH-1 expression: a case report and literature review. *Stem Cell Investig* 2018;5:7.